 is moving its business development center to the United States. The company's new Director of Business Development will be located in North Kingstown, RI. 

The company hopes that in the current situation Russia will be even more attractive in terms of clinical trials for American small and mid-sized sponsors. 

“We have always emphasized that one of the strategic goals set by SynRG is enhancing of research and investment attractiveness of Russia for foreign sponsors, so business development in the USA is a natural step along this strategic line," says SynRG CEO Igor Stefanov. “We spent quite some time interviewing candidates and conversing with the finalists, and now I am happy to introduce our new Director of Business Development, Anna Ravdel."

 Anna Ravdel has graduated from the University of Manchester with an MBA degree, and worked as a marketing and sales director in various international companies. Prior to joining SynRG, Anna had worked as a Director of Business Development at Evidence Clinical and Pharmaceutical Research (Russia/USA) and at a global CRO Worldwide Clinical Trials.  

SynRG also has plans of opening a Ukrainian office and, probably, a virtual office in Prague, as more and more of their clients are interested in the presence from Eastern European countries to Kazakhstan on a regional level.  